CNTA
Income statement / Annual
Last year (2023), Centessa Pharmaceuticals plc's total revenue was $6.88 M,
and the percentage change from the previous year is not available.
In 2023, Centessa Pharmaceuticals plc's net income was -$151.67 M.
See Centessa Pharmaceuticals plc’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$6.88 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$813,139.00 |
$130,919.00 |
$33,995.00 |
$0.00 |
$0.00 |
| Gross Profit |
$6.07 M |
-$130,919.00 |
-$33,995.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0.88 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$124.89 M
|
$155.08 M
|
$96.31 M
|
$9.30 M
|
$4.26 M
|
| General & Administrative
Expenses |
$53.73 M
|
$55.20 M
|
$43.01 M
|
$1.14 M
|
$790,000.00
|
| Selling & Marketing
Expenses |
-$604,875.00
|
$0.00
|
$42.93 M
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$53.13 M
|
$55.20 M
|
$42.97 M
|
$1.14 M
|
$790,000.00
|
| Other Expenses |
-$5.43 M |
$2.34 M |
$0.00 |
$155,000.00 |
$105,000.00 |
| Operating Expenses |
$178.01 M |
$210.28 M |
$139.28 M |
$10.44 M |
$5.05 M |
| Cost And Expenses |
$178.83 M |
$210.28 M |
$139.31 M |
$10.44 M |
$5.05 M |
| Interest Income |
$10.48 M |
$7,033.00 |
$2,549.00 |
$378.00 |
$5,000.00 |
| Interest Expense |
$9.91 M |
$7.03 M |
$2.55 M |
$378,000.00 |
$118,000.00 |
| Depreciation &
Amortization |
$813,139.00
|
$130,919.00
|
$33,995.00
|
$6,000.00
|
$6,000.00
|
| EBITDA |
-$171.13 M
|
-$207.94 M
|
-$139.28 M
|
-$10.29 M
|
-$4.94 M
|
| EBITDA Ratio |
-24.88 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-24.99
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$4.88 M
|
-$4.69 M
|
-$242.43 M
|
-$223,000.00
|
-$8,000.00
|
| Income Before Tax |
-$176.82 M |
-$216.95 M |
-$381.74 M |
-$10.66 M |
-$5.06 M |
| Income Before Tax Ratio
|
-25.7
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$25.15 M |
-$747,000.00 |
$113,986.00 |
$378,000.00 |
$223,000.00 |
| Net Income |
-$151.67 M |
-$216.21 M |
-$381.85 M |
-$11.04 M |
-$5.28 M |
| Net Income Ratio |
-22.05 |
0 |
0 |
0 |
0 |
| EPS |
-1.58 |
-2.31 |
-4.24 |
-0.0777 |
-0.0745 |
| EPS Diluted |
-1.58 |
-2.31 |
-4.24 |
-0.0777 |
-0.0745 |
| Weighted Average Shares
Out |
$96.18 M
|
$93.40 M
|
$89.99 M
|
$142.06 M
|
$70.89 M
|
| Weighted Average Shares
Out Diluted |
$96.18 M
|
$93.40 M
|
$89.99 M
|
$142.06 M
|
$70.89 M
|
| Link |
|
|
|
|
|
